National Health (Pharmaceutical Benefits) Regulations (Amendment) (Cth)

TRIPLICATE COPY

Ex. Co. Secretariat: please complete this copy ey insertion of signatures and date of making, and send to Legislative Services Section. Legislative Drafting Division, Attorney-General’s Department.

Statutory Rules 1983 No. (

j

National Health (Pharmaceutical Benefits)

Regulations2 (Amendment)

I, THE GOVERNOR-GENERAL of the Commonwealth of Australia, acting

with the advice of the Federal Executive Council, hereby make the following

Regulations under the National Health Act 1953.

Dated 2 3 1983.

N. M. STEPHEN

Governor-General

By His Excellency’s Command,

Minister of State for Health

S.R. 282/83 Cat. No. — Recommended retail price 50c 11/21.11.108.3

Commencement

1. These Regulations shall come into operation on 1 December 1983.

Schedule 1

2. Schedule 1 to the National Health (Pharmaceutical Benefits)

Regulations is amended as set out in Schedule 1.

Schedule 2

3. Schedule 2 to the National Health (Pharmaceutical Benefits)

Regulations is amended as set out in Schedule 2.

Schedule 3

4. Schedule 3 to the National Health (Pharmaceutical Benefits)

Regulations is amended as set out in Schedule 3.

2	National Health (Pharmaceutical Benefits)	1983 No. ^
Schedule 4

5. Schedule 4 to the National Health (Pharmaceutical Benefits)

Regulations is amended as set out in Schedule 4.

Schedule 5

6. Schedule 5 to the National Health (Pharmaceutical Benefits)

Regulations is amended as set out in Schedule 5.

SCHEDULE 1 Regulation 2

AMENDMENTS OF SCHEDULE 1 TO THE NATIONAL HEALTH

(PHARMACEUTICAL BENEFITS) REGULATIONS

1. After item 5 insert the following item:

"5A Adrenaline Solution”.

2. After item 35 insert the following item:

“ 35Λ A m m onia and Ip ec acu a n h a

Mixture”.

3. After item 36 insert the following items:

“36A Ammonia Solution, Dilute

36B Ammonia Solution, Strong

36C Ammonium Acetate Solution, Strong

36D Ammonium Bicarbonate”.

4. After item 48 insert the following item:

"48A Anise Oil”.

5. After item 101 insert the following item:

“ 10! A Benzy(penicillinSodium”.

6. After item 105 insert the following item:

“ 105Λ Betamethasone Sodium

Phosphate Injection".

7. After item 139 insert the following item:

“ 139A Calcium Gluconate".

8. After item 150 insert the following item:

" 150Λ Camphorated Opium Tincture".

9. After item 151 insert the following item:

“ I 51A Camphor Water, Concentrated".

10. After item 188 insert the following item:

“ 188A Chalk".

11. After item 192 insert the following item:

“ 192A Chloral Mixture".

12. After item 236 insert the following item:

“236A Clioquinol Cream".

13. After item 243 insert the following item:

“243A Clove Oil".

14. After item 289 insert the following item:

“289A Cyproheptadine Hydrochloride”.

15. Omit item 294.

16. After item 541 insert the following item:

“541A Hyoscyamus Tincture".

17.

After item 565 insert the following items:

“565A Ipecacuanha Emetic Mixture,

Paediatric

565B Ipecacuanha Liquid Extract”.

National Health (Pharmaceutical Benefits) 1983 No. ^ 3

SCHEDULE 1—continued

18. After item 584 insert the following item:

“584A Lactic Acid".

19. After item 616 insert the following item:

“616Λ Magnesium Carbonate, Heavy”.

20. After item 617 insert the following item:

"617A Magnesium Hydroxide Mixture".

21. After item 618 insert the following item:

“618A Magnesium Oxide, Light”.

22. Omit item 621.

23. After item 622 insert the following item:

“622A Magnesium Trisilicate Oral

Powder, Compound".

24. After item 721 insert the following item:

“721A Norethynodrel".

25. After item 819 insert the following item:

“819A Phenylmercuric Nitrate".

26. After item 858 insert the following item:

“858A Potassium Citrate Mixture”.

27. After item 880 insert the following item:

"880A Procaine Hydrochloride”.

28. After item 913 insert the following item:

“9 13 A Quillaia Tincture".

29. After item 945 insert the following item:

“945Λ Senega Infusion, Concentrated".

30. After item 964 insert the following item:

“964A Sodium Benzoate".

31. After item 982 insert the following item:

“982A Sodium Iodide".

32. After item 987 insert the following item:

“987A Sodium Metabisulphite".

33. After item 1017 insert the following items:

“ 1017A Squill Opiate Linctus

1017B Squill Opiate Linctus, Paediatric

10! 7C Squill Tincture".

34. After item 1154 insert the following item:

“ 1154A White Liniment".

SCHEDULE 2 Regulation 3

AMENDMENTS OF SCHEDULE 2 TO THE NATIONAL HEALTH

(PHARMACEUTICAL BENEFITS) REGULATIONS

1. Omit item 36.

2. After item 46, insert the following item:

“46A Calcium Carbonate, B.P. Calcium Lactate-Gluconate with Calcium

Carbonate, B.P.

Citric Acid Monohydrate, B.P., with Calcium

Carbonate, B.P.”.

3. After item 53, insert the following item:

“53A Chloral Hydrate, B.P. —

4. After item 65, insert the following item:

“65A Clioquinol, B.P. Flumethasone Pivalatc with Clioquinol, B.P.”.

4 National Health (Pharmaceutical Benefits) 1983 No.

SCHEDULE 2—continued

5. Omit item 72. 6. Omit item 93.

7. After item 107, insert the following item:

“ 107A Ferrous Gluconate, B.P.

8. Omit item 166, substitute the following item:

"166 Mestranol, B.P. Elhynodiol Diacetate, B.P., with Mestranol,

B.P.

Norethisterone, B.P., with Mestranol, B.P.”.

9. Omit item 179.

10. After item 187, insert the following item:

“ 187A Paracetamol, B.P. Codeine Phosphate, B.P., with Paracetamol,

B.P.”.

11. After item 192, insert the following item:

“ 192Λ Phenylephrine Hydrochloride, B.P. Prednisolone Acetate with Phenylephrine

Hydrochloride, B.P.

Zinc Sulphate, B.P., with Phenylephrine

Hydrochloride, B.P.".

12.

After item 194, insert the following item:

“ 194.A Physostigmine Salicylate, B.P.

13. After item 201, insert the following item:

"201A Potassium Chloride, B.P.	Anhydrous Glucose, B.P., with Sodium Chloride, B.P., Citric Acid, B.P., Sodium Citrate, B.P., and Potassium Chloride, B.P.
Sodium Lactate with Anhydrous Glucose, B.P.,

and Potassium Chloride, B.P.

Sodium Chloride, B.P., with Sodium Acetate,

B.P., Sodium G luconate, M agnesium

Chloride, B.P., and Potassium Chloride, B.P.

Sodium Chloride, B.P., with Calcium Chloride,

B.P., and Potassium Chloride, B.P., in Water

for Injections”.

14. Omit item 206, substitute the following item:

"206 Procaine Penicillin, B.P. B e n z a th in e P e n ic i l l i n, B .P ., w ith

Benzylpenicillin Potassium, B.P., and Procaine Penicillin, B.P., in Water for Injections”.

15. Omit item 209.

16.

After item 220, insert the following item:

“220A Sulphacetamide Sodium, B.P.

SCHEDULE 3 Regulation 4

AMENDMENTS OF SCHEDULE 3 TO THE NATIONAL HEALTH

(PHARMACEUTICAL BENEFITS) REGULATIONS

1. Omit item 5. 2. Omit item 15. 3. Omit item 16. 4. Omit item 17.

5. After item 50 insert the following item:

“50a Camphor Spirit, Compound, A.P.F.”.

6. Omit item 89. 7. Omit item 98.

National Health (Pharmaceutical Benefits) 1983 No. 5

SCHEDULE 3 —continued

8. Omit item 116.

9. After item 164 insert the following item:

“ 164a M ethyl Salicylate O intm ent,

Compound, A.P.F. 1934”.

10. Omit item 183. 11. Omit item 213.

12. After item 225 insert the following item:

“225a Red Syrup, A.P.F.”.

13. Omit item 227. 14. Omit item 234. 15. Omit item 239. 16. Omit item 241. 17. Omit item 244.

SCHEDULE 4 Regulation 5

AMENDMENTS OF SCHEDULE 4 TO THE NATIONAL HEALTH

(PHARMACEUTICAL BENEFITS) REGULATIONS

1. Omit item 6. 2. Omit item 16.

3. Omit item 20, substitute the following item:

“20 Peppermint Water, Concentrated, A.P.F.".

SCHEDULE 5 Regulation 6

AMENDMENTS OF SCHEDULE 5 TO THE NATIONAL HEALTH

(PHARMACEUTICAL BENEFITS) REGULATIONS

1. Omit item 43, substitute the following items:

“43 Cimetidine, Tablets, 200 mg With the written authority of the Permanent

Head —

Duodenal ulcer, confirmed by radiology,

endoscopy or surgery

Gastric ulcer, confirmed by radiology,

endoscopy or surgery

Zollinger-Ellison syndrome, proven by

investigation

43a Cimetidine, Tablets, 400 mg With the written authority of the Permanent

Head—

Duodenal ulcer, confirmed by radiology,

endoscopy or surgery

Zollinger-Ellison syndrome, proven by

investigation”.

2. After item 54, insert the following item:

“54a Demeclocyciine Capsules, B.P. With the written authority of the Permanent

Head—

Syndrome of inappropriate antidiuretic hormone secretion, caused otherwise than by treatment with a drug”.

3. Omit item 66. 4. Omit item 68.

Κ-ΎΛ/

6 National Health (Pharmaceutical Benefits) 1983 No. (L

SCHEDULE 5—continued

5. Omit item 95, substitute the following item:

“95 Lactulose With the written authority of the Permanent

Head—

H epatic coma or pre-com a (chronic

porto-systemic encephalopathy)

Terminal malignant neoplasia”.

6. After item 141, insert the following item:

“ 141a (1) Phenylbutazone, B.P. With the written authority of the Permanent

(2) Phenylbutazone H e a d -

Suppositories, B.P. Acute gout

(3) Phenylbutazone Rheumatoid arthritis

Tablets, B.P. Sero-negative spon d y lo -arth ro p ath ies

(an k y lo s in g s p o n d y li tis, R e i te r ’s syndrome, psoriatic arthritis and arthritis associated with chronic inflammatory bowel disease)".

7. Omit item 162, substitute the following item:

“ 162 Sodium Cromoglycate, B.P., Eye With the written authority of the Permanent

Drops Head—

Vernal kerato-conjunctivitis".

8. Omit item 164, substitute the following item:

"1 6 4 Sodium C ro m o g ly ca te, B .P., With the written authority of the Permanent For use in a power-operated nebuliser for the treatment of asthma in children who have not attained the age of eight (8) years".

Nebuliser Solution Head—

NOTES

3 0 Mg o OjiaW /'

1. Notified in the Commonwealth o f A ustralia Gazette on L 1983.

2. Statutory Rules 1960 No. 17 as amended to date. For previous amendments see Note 2 to Statutory Rules 1983 No. 28 and see also Statutory Rules 1983 Nos. 28, 102 and 116.

Printed by Authority by the Commonwealth Government Printer